tetano
Editor, Senior Moderator
J Dermatol
. 2022 Feb 28.
doi: 10.1111/1346-8138.16326. Online ahead of print.
Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases
Hideo Hashizume[SUP] 1 [/SUP], Sayaka Ajima[SUP] 1 [/SUP], Yuto Ishikawa[SUP] 1 [/SUP]
Affiliations
Abstract
Immunoglobulin (Ig)A vasculitis/nephropathy is a systemic immune complex-mediated vasculitis. Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is widely recommended in individuals without specific allergy to the vaccine components, it is arguable whether vaccination is advisable for patients with IgA vasculitis or for predisposed individuals. We and others have presented cases of IgA vasculitis occurring after SARS-CoV-2 vaccination. In total, these 19 cases, including ours, involved predominantly female patients, and half of them were suffering from de novo vasculitis onset. The most frequent manifestation was gross hematuria (89.5%) while skin lesions were relatively infrequent, occurring in only five cases (26.3%), of which three (15.8%) were confirmed to be IgA vasculitis. Taken together, these cases suggest that SARS-CoV-2 vaccination might be a trigger for development/deterioration of IgA vasculitis/nephropathy.
Keywords: de novo onset; deterioration; immunoglobulin A nephropathy; immunoglobulin A vasculitis; severe acute respiratory syndrome coronavirus 2 vaccination.
. 2022 Feb 28.
doi: 10.1111/1346-8138.16326. Online ahead of print.
Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases
Hideo Hashizume[SUP] 1 [/SUP], Sayaka Ajima[SUP] 1 [/SUP], Yuto Ishikawa[SUP] 1 [/SUP]
Affiliations
- PMID: 35229346
- DOI: 10.1111/1346-8138.16326
Abstract
Immunoglobulin (Ig)A vasculitis/nephropathy is a systemic immune complex-mediated vasculitis. Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is widely recommended in individuals without specific allergy to the vaccine components, it is arguable whether vaccination is advisable for patients with IgA vasculitis or for predisposed individuals. We and others have presented cases of IgA vasculitis occurring after SARS-CoV-2 vaccination. In total, these 19 cases, including ours, involved predominantly female patients, and half of them were suffering from de novo vasculitis onset. The most frequent manifestation was gross hematuria (89.5%) while skin lesions were relatively infrequent, occurring in only five cases (26.3%), of which three (15.8%) were confirmed to be IgA vasculitis. Taken together, these cases suggest that SARS-CoV-2 vaccination might be a trigger for development/deterioration of IgA vasculitis/nephropathy.
Keywords: de novo onset; deterioration; immunoglobulin A nephropathy; immunoglobulin A vasculitis; severe acute respiratory syndrome coronavirus 2 vaccination.